FDA Clearance Tracker · P110022-S031
Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgM
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Nov 22, 2024
Approved
Time to decision
266 days
Received Mar 1, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class II
The decision
- FDA number
- P110022-S031
- Device name
- Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgM
- Applicant
- Roche Diagnostics Corp.
- Applicant location
- Indianapolis, IN
- Received
- Mar 1, 2024
- Decided
- Nov 22, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P110022
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the migration of the Elecsys anti-HBc IgM from the cobas e601 and cobas e411 analyzers to the cobas e402 analyzer, for the update to the biotin interference, and for a room temperature sample stability claim.
Source documents
Other decisions for Roche Diagnostics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.